COGT Share Price Performance
Recent COGT News & Updates
No updates
Cogent Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.93
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Cogent Biosciences, Inc. Competitors
About COGT
- Founded
- n/a
- Employees
- 205
- CEO
- WebsiteView website
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.7%
- 1 Year: 17.5%
- Year to Date: 5.9%
The market has dropped by 18% in the last 7 days, with the Financials sector leading declines. In contrast to the last week, the market is actually up 18% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading